Search results
Results from the WOW.Com Content Network
Person with cirrhosis and associated pain in the right upper region of the abdomen. Cirrhosis can take quite a long time to develop, and symptoms may be slow to emerge. [13] Some early symptoms include tiredness, weakness, loss of appetite, weight loss, and nausea. [13] Early signs may also include redness on the palms known as palmar erythema ...
The management of lipodermatosclerosis may include treating venous insufficiency with leg elevation and elastic compression stockings. [9] In some difficult cases, the condition may be improved with the additional use of the fibrinolytic agent, stanozol. Fibrinolytic agents use an enzymatic action to help dissolve blood clots.
Treatment is aimed at opening the blocked veins to minimize complications; the duration of clot (acute versus chronic) affects treatment. Unless there are underlying reasons why it would be harmful, anticoagulation ( low molecular weight heparin , followed by warfarin ) is often initiated and maintained in patients who do not have cirrhosis.
Non-alcoholic fatty liver disease is a spectrum of disease associated with obesity and metabolic syndrome. [9] Hereditary diseases that cause damage to the liver include hemochromatosis, [10] involving accumulation of iron in the body, and Wilson's disease.
Primary biliary cholangitis (PBC), previously known as primary biliary cirrhosis, is an autoimmune disease of the liver. [1] [2] [3] It results from a slow, progressive destruction of the small bile ducts of the liver, causing bile and other toxins to build up in the liver, a condition called cholestasis.
Cirrhosis is a late stage of serious liver disease marked by inflammation (swelling), fibrosis (cellular hardening) and damaged membranes preventing detoxification of chemicals in the body, ending in scarring and necrosis (cell death). [11] Between 10% and 20% of heavy drinkers will develop cirrhosis of the liver (NIAAA, 1993).
No effective medical treatment for primary sclerosing cholangitis is known. Its most definitive treatment is a liver transplant, [1] but disease recurrence can occur in 25–30% of cases. [6] PSC is a rare disease and most commonly affects people with IBD. [2]
Liver cirrhosis can develop in about 7% to 40% of treated patients. People with the highest risk for progression to cirrhosis are those with incomplete response to treatment, treatment failure, and multiple relapses. Once cirrhosis develops, management of liver cirrhosis in autoimmune hepatitis is standard regardless of etiology.